抗胆碱能药物在临床上用来治疗帕金森氏病已有一百余年的历史,它们通过阻断纹状体内胆碱能突触的毒蕈碱样受体(M—受体),降低胆碱能活动,以改善帕金森氏病的症状。根据大量动物实验和心理药理学研究,普遍认为中枢胆碱能系统在学习和记忆中有重要的作用。加强或削弱中枢胆碱能系统功能活性的药物可能对于学习和记忆功能产生不同程度的影响。因之当应用抗胆碱能药物治疗帕金森氏病患者,在治疗的过程中出现智力障碍时,后者究属疾病本身进展所 Anticholinergics have been used clinically for more than a century to treat Parkinson’s disease by blocking the cholinergic synaptic muscarinic receptors (M-receptors) in the striatum, , Reduce cholinergic activity, to improve the symptoms of Parkinson’s disease. According to a large number of animal experiments and psychopharmacology, it is generally accepted that the central cholinergic system plays an important role in learning and memory. Drugs that strengthen or weaken the functional activity of the central cholinergic system may have varying degrees of impact on learning and memory. Therefore, when the application of anticholinergic drugs in patients with Parkinson’s disease, mental retardation in the course of treatment, the latter belongs to the progress of the disease itself